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ABSTRACT
Objective The first wave of the COVID-19 pandemic had 
a major impact on healthcare utilisation. The aim of this 
retrospective review was to quantify how utilisation of 
non- COVID care changed during this time so as to gain 
insight and inform planning of future services during 
potential second and subsequent waves.
Methods and analysis A longitudinal design was used 
to analyse anonymous private UK health insurer datasets 
covering the period of January 2018 to August 2020. 
Taken as a measure of healthcare utilisation in the UK, 
incidence rates of claims broken down by service area and 
condition were calculated alongside overall monthly totals 
and costs. Pre- COVID-19 years were compared with the 
current year.
Results Healthcare utilisation during the first wave of 
COVID-19 decreased by as much as 70% immediately 
after lockdown measures were implemented. After 
2 months, the trend reversed and claims steadily began to 
increase, but did not reach rates seen from previous years 
by the end of August 2020. Assessment by service and 
diagnostic category showed that most areas, especially 
those highly reliant on in- person treatment, reflected 
the same pattern (ie, rapid drop followed by a steady 
recovery). The provision of mental health services differed 
from this observed trend, where utilisation increased by 
20% during the first wave of COVID-19, in comparison to 
pre- COVID-19 years. The utilisation of maternity services 
and the treatment of existing cancers also stayed stable, 
or increased slightly, during this time.
Conclusions Healthcare utilisation in a UK- based 
privately insured population decreased dramatically during 
the first wave of the COVID-19 pandemic, being over 
70% lower at its height. However, mental health services 
remained resilient during this time, possibly due to greater 
virtualisation of diagnostics and care.
INTRODUCTION
In the aftermath of the first wave of the 
novel COVID-19, it is clear the impact of 
the global pandemic on healthcare systems 
has been acute.1 Most systems, regardless of 
location, have had to take immediate action 
ranging from rapid transitions to virtual 
care2 to complete shutdowns. Fear of infec-
tion and reduced availability of healthcare 
services has led to reduced non- COVID 
healthcare utilisation worldwide. In Italy 
and Germany,3 4 paediatric emergency room 
(ER) visits dropped by as much as 64%–88% 
while heart attack treatment rates in the USA 
decreased by 38% in some major hospitals.5
In the UK, the first identified cases of 
COVID-19 were reported at the end of 
January 2020, but the first person- to- person 
transmission was only confirmed in late 
February.6 On 11 March, WHO declared 
the spread of COVID-19 a pandemic and 
measures were taken nationally to slow the 
spread and protect healthcare systems. A UK 
national lockdown started on March 23rd 
and the public were informed to only to leave 
their homes for specific reasons such as food 
shopping, travel to work, once daily exercise 
and urgent medical needs.6 Further restric-
tions were imposed by mid- April.6
In addition to limiting population move-
ment, physical distancing outside of the home 
was also advised and this perhaps triggered 
the beginning of the changes in healthcare 
utilisation by individuals. When considering 
visiting a hospital or clinic, members of the 
public were now tasked with weighing their 
risk of travelling, as well as visiting a setting 
which was a potential hotspot for infection. 
From the provider perspective, there was a 
scramble to triage the most urgent, but also 
Strengths and limitations of this study
 ► This longitudinal study evaluated healthcare utilisa-
tion within a private healthcare sample over 3 years 
enabling insight into health seeking behaviours 
during the first COVID-19 wave.
 ► Real- world monthly claims data for both service 
type and diagnostic category was assessed en-
abling comparative analysis.
 ► The data were limited to a population that were pri-
vately insured within a country where the majority 
use the government funded National Health Service.
 ► Although costs were analysed it was not possible 
to confirm whether other variables such as medical 
inflation or contracted rates might have influenced 
the unit cost of care or frequency of claims.
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the least at- risk patients, for in- person consultation. The 
challenge of providing healthcare during a pandemic 
for those with compromised immune systems7 8 has 
been a global issue. The short- term impact of COVID-19 
has directly affected many individuals who have been 
infected, but also the wider population looking to access 
healthcare during this time.9
In the UK, approximately 10.5% of consumers have 
private medical insurance.10 There is little debate in rela-
tion to how severely most healthcare systems have been 
disrupted but the areas and services that have been able 
to adapt most effectively, often with the use of virtual care, 
may provide potential solutions for areas still lagging 
behind. This is especially critical at the moment as the 
UK has already experienced a second wave of COVID-19 
infections where lockdown measures have been reimple-
mented11 and there are concerns about preparing for a 
third wave. In this study we sought to review trends in 
claims and costs for patient care collected over the past 
year up to the end of the first wave. The aim was to explore 
changes in how people were utilising care in comparison 
to previous years so as to assess overall stability. In the 
wake of the second wave of COVID-19, understanding 
where resources might be best directed could lead to an 
improved ‘non- COVID’ healthcare response.
METHODS
Study design and data sources
A longitudinal design was used to analyse frequency of 
healthcare service claims in the UK. This was not longitu-
dinal in the sense that the same individuals were followed 
over time, rather it was the fully insured served population 
from one UK private health insurer. A prepared dataset 
was obtained from this insurance provider operating in 
the UK. The health insurance provider is only one of 
two providers that offer only employer sponsored cover 
with no direct to consumer products. The businesses that 
make up the clientele predominately consist of corporate 
or white- collar employee organisations across the UK. As 
it was not raw data and had been prepared in advance, 
we did not have to contend with missing data. Data were 
extracted in the form of monthly total number of claims, 
monthly total claimants, monthly total enrolled member-
ship and provider billed costs for the period of January 
2018 through to the end of August 2020. These data 
were then disaggregated into monthly totals by service 
area (eg, physiotherapy or specialist consultation) and 
condition (eg, musculoskeletal or mental disorders). 
For the frequency counts of monthly claims, it must be 
clarified that these do not represent medical encounters 
but instead a claim in a relevant pre- determined category 
according to the billing system of the insurance provider. 
As an example, someone requiring surgery may have 
claims in at least two categories according to service (eg, 
theatre charges and surgeon fees) for only one medical 
encounter.
The data from 2018 and 2019 from the same relative 
time period were averaged and considered to represent 
a typical ‘pre- COVID-19’ year. The data from 2020 were 
classified as the ‘COVID-19’ year.
Patient and public involvement
Patients were not actively recruited for this study as it was 
secondary use of an existing dataset and it contained no 
identifying or personal information at any point. As it 
was analysed and processed anonymously, clients and the 
public were not directly involved in this study.
Statistical analysis
As the ratios for each month varied based on fluctu-
ating membership, the monthly frequency of claims was 
calculated as the frequency of claims per 1000 enrolled 
members. This frequency was calculated by 1000 × 
[monthly number of claims total ÷ monthly membership] 
for monthly totals. The frequency for claims by service 
and condition categories was also calculated in the same 
way. Changes in frequencies between the ‘pre- COVID-19’ 
year (January through August in 2018 and 2019 averaged) 
and the ‘COVID-19’ year (January through August 2020) 
were calculated as a percentage based on the per 1000 
incident rates. The calculation was [incident rate differ-
ence ÷ first incident rate] × 100. Finally, percentage of 
claimants and corresponding costs by month of enrolled 
members from 2018 to 2019 to 2020 were calculated 
based on monthly totals of enrolled. Inferential statistical 
tests were not used in our study because it was a descrip-
tive analysis using longitudinal data from the whole popu-
lation rather than a sample.
RESULTS
The mean age of the population was 42.1 (±11.5 years) 
ranging from 20 to 65 years with an average of 52.4% 
being males. While not being able to confirm exact 
membership enrolment or divulge employer details, as 
this is industry sensitive information, it is possible to report 
that the minimum average monthly membership was 
>260 000 with a maximum of just under 300 000. Based on 
frequency of claims per 1000 enrolled members, monthly 
totals for the pre- COVID-19 year and the COVID-19 year 
can be seen in table 1. Online supplemental material 
including a breakdown by service (online supplemental 
table S1) and condition (online supplemental table S2) 
at a monthly level is available. The biggest shift in claims 
frequency was directly after lockdown in the UK which 
started in late March. By the end of April, the rate of 
claims had decreased by almost 70% in comparison to 
the pre- COVID-19 years. To offer context, January and 
February 2020, reported slight increases and while March 
had a reported decrease in claims, it was only by 13%. 
The impact of COVID-19 was most prominent in April 
and continued through to August where the overall 
claims rate was 42% less (at a rate of 54.8 claims per 1000 
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enrolled members) than the previous year (which was 
95.0 claims per 1000 enrolled members).
The biggest decreases of the year for claims can be 
seen in May when the most restrictions had been applied 
across the general population.
In table 2, monthly calculated percentage of claim-
ants demonstrate the same trend. Claimant numbers as 
a percentage of the covered population were approx-
imately the same across the pre- COVID-19 years and 
COVID-19 year, in January and February. This shifted in 
March 2020 and the percentage of claimants dropped for 
the first time (by 1%) compared with the pre- COVID-19 
years. This decrease continued until May where a 
maximum decrease of 5% was recorded. Costs (in GB 
pounds) per claimant varied on a monthly basis across 
both pre- COVID-19 and COVID-19 years, but were not 
outside of the normal month- to- month variation seen in 
the pre- COVID period.
Frequency of claims by condition
The total claims per 1000 enrolled members can be 
seen below in table 3 as broken down by 16 condition 
areas. The largest decrease in claims by condition was 
seen for respiratory system diseases. This condition area 
decreased overall by almost 51% compared with previous 
years. Closely following this rate of decrease were condi-
tions which all had decreases of over 40% (but less than 
50%). These five conditions were general injury and/or 
poisoning (46%) and diseases of the circulatory (45%), 
nervous (44%), digestive (43%) and musculoskeletal 
(41%) systems. Other decreases over 20% (but under 
40%) included conditions ranging from skin disease 
(38%) to endocrine, nutritional and metabolic condi-
tions at 30%. After this, moderate to small decreases 
were found for categories including a vague ‘symptom, 
signs, ill- defined condition’ group (19%), neoplasm 
(13%), blood diseases (9%) and unknowns categorised 
as ‘others’ (3%). In contrast to all other conditions, preg-
nancy/childbirth and mental disorders increased overall 
in claims frequency by approximately 4% and 20%, 
respectively.
When assessing rankings in table 3, it can be seen that 
overall, the top ranked conditions, stayed the same in 
the COVID-19 year compared with previous years. Both 
pre- COVID-19 and COVID-19 years had musculoskeletal 
disease, the general ‘symptoms, signs, ill- defined’ cate-
gory and neoplasm conditions with the highest incident 
rates per 1000 enrolled members. The real changes were 
more subtle with mental disorders moving up a place 
from fifth to fourth highest number of claims and a 
moderately larger gap between the top four conditions 
compared with all others. In the COVID-19 year this gap 
Table 1 Frequency of claims by month per 1000 enrolled 
members from 2018/2019* to 2020
Month
Pre- COVID-19 
year*
COVID-19 
year
Difference in 
claims/1000 
enrolled, %
January 194.0 215.7 11
February 175.4 199.3 14
March 189.3 165.1 −13
April 167.7 51.7 −69
May 180.3 50.2 −72
June 165.7 73.5 −56
July 158.8 100.5 −37
August 95.0 54.8 −42
*Average of 2018 and 2019.
Table 2 Percentage of population who were claimants and 
monthly costs per claimant for 2018/2019* and 2020
Month
Pre- COVID-19 year* COVID-19 year
Change in 
claimants 
by %
Claimants 
by %
Average 
cost per 
claimant
Claimants 
by %
Cost 
in £
January 6.2 £867 6.4 £851 0.2
February 6.1 £793 6.3 £798 0.3
March 6.4 £815 5.4 £829 −1.0
April 6.1 £753 2.0 £701 −4.1
May 6.4 £789 1.9 £818 −4.5
June 6.2 £782 2.7 £908 −3.5
July 6.2 £815 3.6 £906 −2.6
August 5.8 £797 3.4 £798 −2.4
*Average of 2018 and 2019.
Table 3 Frequency of claims by condition and change in 
percentage from 2018/2019* to 2020
Condition
Pre- COVID-19 
year*
COVID-19 
year
Change 
in %
Respiratory system disease 26.5 13.0 −50.8
Injury and poisoning 89.4 48.1 −46.2
Circulatory system disease 36.3 20.0 −44.9
Nervous system disease 60.2 33.7 −44.1
Digestive system disease 74.2 42.3 −42.9
Musculoskeletal system 
disease
483.9 283.5 −41.4
Skin and subcutaneous 
disease
33.6 21.0 −37.6
Genitourinary system disease 96.6 62.4 −35.5
Infectious and parasitic 
disease
2.9 1.9 −35.1
Endocrine, nutritional, 
metabolic disease
10.4 7.3 −29.7
Symptoms, signs, ill- defined 
conditions
182.1 146.7 −19.4
Neoplasms 127.9 111.6 −12.8
Blood diseases 2.3 2.1 −8.7
Others 5.0 4.9 −2.9
Pregnancy, childbirth 4.6 4.8 4.3
Mental disorders 90.0 107.6 19.6
*Average for 2018 and 2019.
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was larger with previous years having a difference of only 
seven claims/1000 enrolled members and the COVID-19 
year having a difference of more than 45 claims/1000 
enrolled members.
Frequency of claims by service
The total claims per 1000 enrolled members can be seen 
below in table 4 as broken down by service (see online 
supplemental file 2) for a brief description of service 
categories). The largest decrease in claims was in relation 
to theatre charges, which corresponds with restrictions 
to elective surgical procedures during this time. Closely 
following this was physiotherapy (48%), surgeon/anaes-
thetist services (47%), package pricing (44%) and accom-
modation/consumables (43%) categories, all of which 
are related to surgical intervention or in- person delivery 
of care.
The next group of decreases were relatively moderate, 
mostly ranging from 31% to 41%. The services included 
in this group were highly varied in type of claims and 
included chiropractic/osteopathy services (40%), cash 
benefits (35%) and specialist consultations (30%). 
Of the areas that decreased from previous years, only 
specialist services and diagnostic services were less than 
30%, with rates of 28% and 17%, respectively. Finally, two 
service areas contrasted the other trends and increased 
in comparison to previous years for claims by service. 
Chemotherapy/radiotherapy increased by 13.6% overall 
and mental health services increased by 20% compared 
with previous years.
When assessing rankings in table 4, the overall top 
ranked services were physiotherapy, specialist consul-
tations, diagnostic services and surgeon/anaesthetist 
services. These were all over 100 claims/1000 enrolled 
members with only one group (ie, surgeon/anaesthe-
tist services) being under the 200 claims. Ranking for 
highest number of claims in the COVID-19 year were 
slightly different with four services over 100 claims/1000 
enrolled but only one service (ie, diagnostic services) 
over 200 claims which closely follows the general trend 
of decreased claims. The notable group of psychiatric 
service that contrastingly increased during the COVID-19 
year (by 20%) also rose up in the ranks from the 5th to 
4th highest claim number with 108 claims/1000 enrolled.
Like the condition rates, changes within the group rank-
ings overall were subtle with gaps between rankings being 
wider in the COVID-19 year versus the pre- COVID-19 
year. During the pre- COVID-19 years, the difference 
between rankings after the top 4 to 5 ranked services, was 
relatively gradual with no more than 25 claims difference 
between rankings and most commonly about 10 claims. 
During the COVID-19 year, this change with a strong 
divide between the top four ranked services, the lowest 
of which was 108 claims/1000 enrolled (ie, psychiatric 
service) and the next rank down which was almost half 
that amount with 57 claims/1000 enrolled.
DISCUSSION
The impact of COVID-19 has challenged healthcare 
systems worldwide. During the first wave of the pandemic 
the UK experienced the highest mortality rate in Europe, 
closely followed by Belgium, Italy and Spain.1 This study 
sought to explore the UK’s response in healthcare utili-
sation as measured by frequency of claims submitted to 
a private health insurer. Our aim was to tease out poten-
tial trends that might shed light on how the first wave 
impacted healthcare provision so as to potentially support 
response planning during subsequent waves.
Claims submitted in 2020, from January through 
August, which captured the build- up and completion of 
the first COVID-19 wave, were compared with the average 
of two previous years for the same time period. Our find-
ings show that the trends in healthcare utilisation in the 
UK private sector reflect that which has been reported 
globally.12–14 Our data show a sizeable drop in care utilisa-
tion for almost all services and diagnostic categories. The 
exception to this trend being for those with mental health 
and maternity needs, as well as those requiring chemo-
therapy and radiotherapy services.
During the first wave of the pandemic the UK’s National 
Health Service (NHS) and the private health sector 
worked in collaboration to ensure individuals received 
care based on clinical need, rather than funding origin. 
With many NHS hospitals focused solely on managing 
patients with COVID-19 private sector providers treated 
many NHS patients based on the agreed clinical necessity 
criteria. This meant that regardless of whether a patient 
had private insurance or not, all patients were triaged to 
access care in the same way. Our data could therefore 
be considered to be a reasonable representation of the 
Table 4 Frequency of claims by service and change in 
percentage from 2018/2019 to 2020
Service
Pre- COVID-19 
year*
COVID-19 
year
Change 
in %
Theatre charges 47.7 21.4 −55.2
Physiotherapy 282.5 147.4 −47.8
Surgeons and anaesthetist fees 107.7 57.3 −46.8
Package pricing 19.5 10.8 −44.3
Accommodation/consumables 61.6 35.1 −42.9
Others 33.3 19.7 −40.8
Chiro/osteopathy 50.6 30.4 −39.9
Cash benefit 23.0 15.0 −34.7
Treatment room charges 43.1 28.6 −33.8
GP consultations 2.2 1.5 −33.7
Specialist consultations 279.5 193.9 −30.6
Specialist fees 15.1 10.9 −28.1
Diagnostic services 250.7 208.9 −16.7
Chemotherapy/radiotherapy 19.0 21.6 13.6
Psychiatric 90.6 108.4 19.6
*Average of 2018 and 2019.
GP, general practitioner.
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impact of the pandemic on the different aspects of non- 
COVID care across the nation. This means the data for 
this study did not include any COVID-19- related care util-
isation. Combined with public health measures (eg, lock-
down and masking) that potentially reduced the influenza 
season, this may in some part explain why the respiratory 
conditions showed the largest drop in utilisation in this 
private healthcare analysis. Along the same lines, the 
category of injury (and poisoning) saw the second largest 
reduction, which may also have been influenced by lock-
down measures severely limiting physical activities.
There has been much written in the scientific liter-
ature and popular press about how the pandemic, and 
the consequent reduction in care provision, has had a 
profound impact on the timeliness of diagnosing and 
treating may conditions, including cancer.15 Our findings 
suggest that there was an appreciable reduction in new 
claims for neoplasms (12.8%), which is likely to reflect 
a delay in diagnosing individuals with cancer. However, 
we did see a relative increase in the number of claims for 
cancer treatment in the form of chemotherapy and radio-
therapy, suggesting that those patients who already had a 
diagnosis at the time of lockdown were not impacted to 
the same degree.
Another area where substantial change in claims 
activity was seen is that of psychological and emotional 
health. Considerable concern has been raised in relation 
to mental health during the course of the pandemic, 
with the associated physical distancing and quarantining 
requirements exacerbating existing mental health issues 
and potentially contributing to new ones.16 A recently 
published study comparing mental health trends longitu-
dinally for over 40 000 participants found that by the end 
of April 2020, the quality of the mental health of adults 
in the UK had decreased in comparison to pre- COVID-19 
years.17 Our research very much supported this across 
claims in both the conditions and services categories. 
Under the condition category of mental disorders and 
under the service category of psychiatry, rates of claims 
at the start of the year were found to be slightly higher 
than previous years, but unlike other years, the trend did 
not decrease. In contrast to almost all other claim areas 
by April both categories had increased compared with 
pre- COVID-19 years. This is perhaps the most poignant 
take away for future risk management within health-
care. While better treatment strategies for hospitalised 
COVID-19 patients are being developed and early vaccine 
results are promising,18 19 the deterioration of mental 
health appears to be widespread17 regardless of infection 
status. It is worth noting that remote delivery of psycho-
logical consultations and therapies was commonplace in 
the private healthcare sector, even before the pandemic, 
and it appears that this was rapidly ‘ramped up’ to meet 
the burgeoning demand during this period.
As many countries have now entered a second wave of 
COVID-19 infections and have reimplemented societal 
restrictions, it is clear that care for individuals with non- 
COVID health issues will continue to be impacted. Virtual 
care delivery may help plug some of the diagnostic and 
treatment gaps that will inevitably occur until widespread 
vaccination can be delivered.
Strengths and limitations
A strength of this study is the longitudinal nature of the 
data that was collected, which allowed for a stronger 
comparative analysis. As well, the ability to look at this 
data as both service type and diagnostic category offered 
insight into what was driving any changes in trends and 
which areas were impacted most. In contrast, a weakness 
of this study is that it was limited to a population with 
private health insurance within the UK specifically, with 
our ability to generalise findings to the broader popula-
tion unclear. While it is essential to have quantitative data 
addressing objective health behaviours (ie, submitted 
healthcare claims), ideally qualitative data in relation to 
what motivated people to change their health seeking 
behaviours would also have been advantageous. As it 
stands, the data was only able to offer a descriptive snap-
shot of this unique time period and without more gran-
ular information in relation to potential confounding 
variables, a more complex analysis was not possible.
CONCLUSIONS
Overall, our findings reflect the direct impact of 
COVID-19 on healthcare delivery systems across the UK, 
with a sudden decrease in utilisation being observed in 
April and May immediately following the implementa-
tion of lockdown measures. The steady recovery after this 
time up until August indicates a level of resilience for all 
types of service. As we enter the second wave of COVID-19 
infections we have a real opportunity to strengthen the 
provision of non- COVID care across all service and diag-
nostic categories. The relative success of the provision 
of psychological healthcare services is a potential blue-
print for others to use so that traditional face- to- face care 
is augmented, and potentially sometimes replaced, by 
virtual delivery methods.
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Table S1. Frequency of claims by condition data per 1000 enrolled members from 2018 to 2019* to 2020 
Service Year Jan Feb Mar Apr May Jun Jul Aug 
Musculoskeletal system  
Pre 70.8 64.6 68.6 60.9 64.8 60.2 58.3 35.8 
Post 73.4 68.2 51.8 9.4 10.4 19.4 31.9 19.0 
Symptoms, signs, & ill-
defined conditions 
Pre 23.0 21.6 23.4 22.4 23.8 24.4 27.0 16.5 
Post 38.7 34.3 27.1 6.0 6.7 10.3 15.1 8.6 
Neoplasms 
Pre 19.5 17.2 18.7 16.1 16.5 15.4 15.5 9.0 
Post 20.5 18.2 19.1 10.2 11.0 13.3 13.4 6.0 
Mental disorders 
Pre 14.6 12.9 14.6 12.6 13.8 10.2 7.9 3.3 
Post 18.8 18.1 19.4 16.1 10.8 10.7 9.7 4.0 
Genitourinary  
Pre 13.8 13.0 13.9 12.4 13.1 12.2 10.9 7.3 
Post 14.7 13.7 10.8 2.6 2.9 5.3 7.7 4.6 
Injury & poisoning 
Pre 13.5 12.2 12.9 11.7 12.4 11.1 9.8 5.7 
Post 11.2 10.8 9.7 2.2 2.1 3.8 5.8 2.6 
Digestive  
Pre 11.7 10.1 11.2 8.8 9.7 8.9 8.5 5.3 
Post 11.1 10.4 7.4 1.1 1.3 2.4 5.2 3.5 
Nervous system 
Pre 8.9 7.8 8.7 7.7 8.9 7.6 6.4 4.0 
Post 8.8 8.1 6.0 0.8 1.1 2.3 4.3 2.2 
Circulatory  
Pre 5.4 5.0 5.0 4.5 5.3 4.9 4.0 2.3 
Post 5.2 4.8 3.6 0.6 1.0 1.7 2.0 1.0 
Skin & subcutaneous 
Pre 5.0 4.1 4.8 4.2 4.9 4.1 4.2 2.4 
Post 4.7 4.9 4.0 1.2 1.1 1.7 2.3 1.2 
Respiratory  
Pre 4.1 3.7 3.7 3.3 3.8 3.4 3.0 1.5 
Post 4.1 3.5 2.4 0.3 0.5 0.6 1.0 0.7 
Endocrine, nutritional & 
metabolic 
Pre 1.5 1.3 1.4 1.3 1.4 1.3 1.3 0.9 
Post 1.7 1.4 1.5 0.3 0.3 0.6 0.9 0.5 
Others 
Pre 0.8 0.5 0.7 0.5 0.6 0.8 0.7 0.4 
Post 1.0 1.1 0.8 0.2 0.2 0.5 0.6 0.4 
Pregnancy & childbirth 
complications 
Pre 0.6 0.6 0.6 0.6 0.7 0.5 0.6 0.2 
Post 1.0 0.9 0.6 0.6 0.6 0.6 0.4 1.0 
Infectious & parasitic  
 
Pre 0.5 0.3 0.5 0.4 0.3 0.4 0.4 0.2 
Post 0.4 0.3 0.4 0.0 0.2 0.2 0.2 0.1 
Blood 
 
Pre 0.3 0.4 0.4 0.4 0.3 0.2 0.3 0.1 
Post 0.4 0.5 0.5 0.1 0.1 0.1 0.2 0.3 
*Average for 2018 and 2019 
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Table S2. Frequency of claims by service data per 1000 enrolled members from 2018 to 2019 to 2020 
Service Year Jan Feb Mar Apr May Jun Jul Aug 
Specialist Consultations 
Pre 40.4 36.1 39.2 35.8 37.4 36.1 34.2 20.3 
Post 43.0 39.3 33.8 10.9 11.3 17.7 23.7 14.3 
Physiotherapy 
 
Pre 39.6 37.0 40.7 36.7 38.2 34.3 34.9 21.3 
Post 38.3 37.9 27.3 6.5 6.1 9.2 13.9 8.2 
Diagnostic  Pre 34.3 31.5 33.1 29.9 32.4 31.5 34.2 23.9 
Post 54.1 48.4 39.4 7.5 8.9 14.8 23.1 12.8 
Surgeons/Anaesthetist 
Fees 
Pre 16.9 14.7 15.6 13.5 14.6 13.9 12.3 6.2 
Post 16.0 14.1 11.2 1.2 1.3 3.1 6.9 3.5 
Psychiatric 
Pre 14.6 13.0 14.7 12.6 14.6 10.1 7.9 3.2 
Post 18.8 18.5 19.3 16.4 10.8 10.8 9.6 4.1 
Accommodation/Consu
mables 
Pre 10.2 8.6 9.1 7.4 7.9 7.6 6.6 4.1 
Post 8.1 7.6 6.5 1.8 2.9 2.6 3.8 1.8 
Treatment Room 
Charges 
Pre 7.5 6.4 6.9 5.7 6.3 6.3 5.3 3.3 
Post 5.9 5.6 4.3 0.3 0.3 0.9 2.7 1.4 
Chiro/Osteopathy 
Pre 7.2 7.1 7.8 6.9 7.4 6.4 5.2 2.6 
Post 7.5 6.5 4.7 0.4 1.5 3.5 4.5 1.9 
Treatment Room 
Charges 
Pre 5.9 5.4 5.8 5.2 6.0 5.4 5.6 3.8 
Post 6.7 6.6 5.1 1.1 1.0 2.2 3.6 2.3 
Others 
Pre 5.3 4.9 4.8 3.8 5.1 4.2 3.6 1.6 
Post 4.9 4.6 3.8 0.7 0.8 1.5 2.5 1.1 
Package Pricing 
Pre 2.8 2.6 2.7 2.4 2.6 2.4 2.5 1.5 
Post 3.3 2.7 2.2 0.2 0.1 0.5 1.2 0.7 
Chemotherapy/Radiothe
rapy 
Pre 2.8 2.5 2.9 2.3 2.5 2.2 2.3 1.4 
Post 2.3 2.8 3.0 2.6 2.9 3.8 2.4 1.7 
Specialist Fees Pre 2.2 1.9 2.2 2.0 2.1 1.8 1.8 1.0 
Post 2.3 1.9 1.8 0.9 0.8 1.2 1.3 0.6 
GP Consultations Pre 0.4 0.3 0.3 0.3 0.3 0.3 0.2 0.1 
Post 0.4 0.4 0.3 0.1 0.1 0.1 0.1 0.0 
*Average for 2018 and 2019 
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Supplementary File 2. Brief Service Categories Description 
 
Diagnostic Services 
 Diagnostic services including pathology, x-rays, scans and any other appropriate tests.  
Specialist Consultations 
 Appointment with a consultant which took place either face-to-face or remotely. 
Physiotherapy 
 Physiotherapy treatment. 
Psychiatric 
 Mainly cognitive behavioural therapy but could include other psychiatric interviews, 
consultations and therapies. 
Surgeons and Anaesthetist Fees 
 Fees charged by a surgeon or anaesthetist as a result of a surgical procedure carried out. 
Accommodation/Consumables 
 The use of an inpatient or day case facility plus any drugs/dressings used during the stay. 
Chiro/Osteo 
 Treatment carried out by a chiropractor or osteopath. 
Treatment Room Charges 
 Charge for services carried out in a treatment room within a facility. 
Theatre Charges 
 Charge for use of an operating theatre including any theatre drugs. 
Chemotherapy/Radiotherapy 
 Treatment using cancer drugs. 
Others 
 Examples include surgical appliances, oncology and Discretionary Benefit Option (DBO). DBO 
is a reimbursement which Cigna has made, at the specific request of the client, for a claim 
which would normally fall outside the terms and conditions of the plan. The most common 
example of this is a surgeon/anaesthetist fee which is above the limit on the Cigna Fee 
Schedule and DBO is applied to cover part or all of the shortfall. 
Cash Benefit 
 A fixed amount that the insurer will pay to a member who elects to receive treatment in an 
NHS facility and, therefore, does not incur medical cost which would otherwise have been 
covered under the plan. 
Package Pricing 
 A combined charge for all elements of a hospital stay including accommodation, theatre 
charges, drugs/dressings and other associated costs. Surgeon/anaesthetist fees for the 
surgical procedure performed is not included in the package price. 
Specialist Fees 
 Fees charged by a specialist for services carried out. 
GP Consultations 
 A private consultation with a general practitioner. 
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